Compare HCWB & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCWB | CELU |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 17.3M |
| IPO Year | 2021 | N/A |
| Metric | HCWB | CELU |
|---|---|---|
| Price | $2.66 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $35.00 | $6.00 |
| AVG Volume (30 Days) | ★ 93.4K | 89.8K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,099,750.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.56 |
| 52 Week High | $7.35 | $4.30 |
| Indicator | HCWB | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 52.65 |
| Support Level | $0.37 | $0.69 |
| Resistance Level | $3.89 | $0.85 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | -0.26 | 0.01 |
| Stochastic Oscillator | 3.05 | 61.76 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.